EDMONTON, Nov. 7 /PRNewswire-FirstCall/ - Isotechnika Inc. announced today the unaudited 24 week data for the Company’s Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247.
EDMONTON, Nov. 7 /PRNewswire-FirstCall/ - Isotechnika Inc. announced today the unaudited 24 week data for the Company’s Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247.